Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) Invested Capital (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Invested Capital for 12 consecutive years, with $183.8 million as the latest value for Q1 2026.

  • For Q1 2026, Invested Capital rose 709.55% year-over-year to $183.8 million; the TTM value through Mar 2026 reached $183.8 million, up 709.55%, while the annual FY2025 figure was $203.0 million, N/A changed from the prior year.
  • Invested Capital hit $183.8 million in Q1 2026 for Crescent Biopharma, down from $203.0 million in the prior quarter.
  • Across five years, Invested Capital topped out at $203.0 million in Q4 2025 and bottomed at -$30.2 million in Q1 2025.
  • Average Invested Capital over 5 years is $67.3 million, with a median of $51.5 million recorded in 2022.
  • On a YoY basis, Invested Capital climbed as much as 9058.6% in 2025 and fell as far as 204.32% in 2025.
  • Crescent Biopharma's Invested Capital stood at $42.9 million in 2022, then fell by 10.52% to $38.4 million in 2023, then tumbled by 103.39% to -$1.3 million in 2024, then skyrocketed by 15692.32% to $203.0 million in 2025, then fell by 9.44% to $183.8 million in 2026.
  • According to Business Quant data, Invested Capital over the past three periods came in at $183.8 million, $203.0 million, and $116.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.